Last reviewed 2026-04-22 · How we verify

PL-ASA

PL-ASA is a combination formulation of aspirin with a protective coating designed to reduce gastrointestinal irritation and bleeding risk while maintaining antiplatelet efficacy.

PL-ASA is a combination formulation of aspirin with a protective coating designed to reduce gastrointestinal irritation and bleeding risk while maintaining antiplatelet efficacy. Used for Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal bleeding.

At a glance

Mechanism of action

PL-ASA uses PLx Pharma's proprietary Phospholipid Surfactant (PLS) technology to coat aspirin, which protects the gastric mucosa from direct contact with aspirin crystals. This formulation aims to preserve aspirin's antiplatelet mechanism of action (inhibition of cyclooxygenase and thromboxane A2 production) while significantly reducing upper gastrointestinal adverse events such as ulcers and bleeding.

Approved indications

• Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal bleeding

Common side effects

• Gastrointestinal bleeding
• Dyspepsia
• Nausea

Key clinical trials

• T-TAS® wS Method Comparison
• High Power Laser on Suboccipital Myoelectrical Activities and Quality of Life in Patients With Cervicogenic Headache (NA)
• The Effects of MLS LASER Therapy in Patients With Chronic Nonspecific Low Back Pain (NA)
• Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects (PHASE2)
• Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers. (PHASE1)
• Pharmacodynamic and Pharmacokinetic Study of PL-ASA (PHASE4)
• Clinical Performance Evaluation of T-TAS 01 PL Chip
• Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.